Discover investment opportunities in Growth Healthcare Stocks In 2025 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Growth Healthcare Stocks In 2025 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Growth Healthcare Stocks In 2025 using our Smart AI Filter.
10 stocks found for "Growth Healthcare Stocks In 2025"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.50 | ±64.8% | -8.0 | 0.00% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
1.02 | ±49.1% | 40.9 | 0.00% | |||
0.64 | ±28.2% | 69.3 | 0.00% | |||
1.34 | ±55.5% | -10.4 | 0.00% | |||
0.30 | ±26.0% | 12.1 | 0.66% | |||
1.77 | ±71.4% | -18.6 | 0.00% | |||
1.19 | ±53.7% | -156.9 | 0.00% | |||
1.92 | ±85.0% | -11.8 | 0.00% | |||
0.83 | ±70.5% | -3.5 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What factors contribute to Vertex Pharmaceuticals' (VRTX) growth potential in the healthcare sector?
A: Vertex Pharmaceuticals focuses on developing innovative treatments for cystic fibrosis and other serious diseases. The company's robust R&D pipeline and established product portfolio suggest solid growth potential, though patent expirations and competitive challenges remain important factors to consider.
Q: How does Regeneron Pharmaceuticals (REGN) manage risks in a rapidly changing biotech industry?
A: Regeneron leverages its strong pipeline and advanced technologies, such as VelocImmune, to maintain a competitive edge. Strategic partnerships and diversification across various therapeutic areas also help mitigate industry risks.
Q: Why is Intuitive Surgical (ISRG) considered a leader in surgical robotics?
A: Intuitive Surgical is a pioneer in robotic-assisted surgery with its da Vinci systems. Its continuous innovation and expansion into new surgical procedures have solidified its market leadership, though high research costs and competition persist as challenges.
Q: What are the investment considerations for Teladoc Health (TDOC) in a post-pandemic world?
A: Teladoc Health expanded significantly during the COVID-19 pandemic. Considerations include sustaining growth as telehealth adoption stabilizes, possible regulatory changes, and competition from larger tech companies entering the telehealth space.
Q: How does Novocure (NVCR) create value in cancer treatment?
A: Novocure specializes in Tumor Treating Fields, a non-invasive cancer therapy. Its innovative approach to treating solid tumors offers strong potential for growth, although clinical trial outcomes and broader market adoption will influence future success.
Q: How might Exact Sciences (EXAS) benefit from trends in early cancer detection?
A: Exact Sciences focuses on early cancer detection through non-invasive tests like Cologuard. Increasing healthcare emphasis on early detection presents growth opportunities, but competition and evolving reimbursement landscapes are potential challenges.